title: [Quadrivalent meningococcal conjugate vaccine].
abstract: Meningoccocal meningitis is still a severe disease. In Switzerland the predominant serotypes are serotype B and C, but this could change as other groups predominate elsewhere. The indications for immunizing against meningococcal infections as described in the Swiss recommendations will be reviewed. New quadrivalent vaccines conjugated with a protein and efficient against serogroup ACWY will soon be available in our country. They show a number of advantages in term of type of protection and should simplify the current vaccination schedule while giving a better coverage against various serogroups, especially for travellers, but also for children at risk for complications.
authors.affiliation: Centre de vaccinations et médecine des voyages, PMU, 1011 Lausanne. Pierre.Landry@hospvd.ch
authors.forename: P
authors.initials: P
authors.lastname: Landry
mesh_terms: D006801:Humans; D008585:Meningitis, Meningococcal / Q000453:epidemiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate
chemical_list: D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate